|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The published findings showed the association between the methylation of SFRP1, SFRP2, and WIF1, located in the Wnt signaling pathway, and the prognosis of CRC were not consistent.
|
31830937 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several gene promoters including SFRP1,2,3, PENK, NPY, ALX4, SEPT9, and WIF1 promoters were found hypermethylated in CRC but not in normal tissues or effluents from fecal donors.
|
31712445 |
2019 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The H‑scores of SLC20A1 were negatively associated with those of Wif1 in somatotroph adenomas (correlation coefficient r=‑0.367).
|
31432167 |
2019 |
|
Nasopharyngeal carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis.
|
31394414 |
2019 |
|
Bladder Neoplasm
|
0.050 |
Biomarker
|
disease |
BEFREE |
The increased methylation levels of WIF1 DNA CpG could be a potential biomarker for bladder cancer.
|
31322264 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
The increased methylation levels of WIF1 DNA CpG could be a potential biomarker for bladder cancer.
|
31322264 |
2019 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
The increased methylation levels of WIF1 DNA CpG could be a potential biomarker for bladder cancer.
|
31322264 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this article, we review the structure, evolution, molecular interactions and functions of WIF1 with major emphasis on its role in carcinogenesis.
|
31210071 |
2019 |
|
Osteoporosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gossypol Promotes Wnt/<i>β</i>-Catenin Signaling through WIF1 in Ovariectomy-Induced Osteoporosis.
|
31139657 |
2019 |
|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia.
|
31006665 |
2019 |
|
Osteosarcoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression of WIF1 was downregulated in osteosarcoma tissues and cell lines.
|
30988764 |
2019 |
|
Osteosarcoma of bone
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression of WIF1 was downregulated in osteosarcoma tissues and cell lines.
|
30988764 |
2019 |
|
Childhood Osteosarcoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression of WIF1 was downregulated in osteosarcoma tissues and cell lines.
|
30988764 |
2019 |
|
Congenital Dysplasia Of The Hip
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
WIF1 expression was compared among different genotypes in DDH patients.
|
30670715 |
2019 |
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of the Wnt inhibitory Factor-1 (WIF1) gene promoter have been detected in different types of cancer.
|
30649640 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of the Wnt inhibitory Factor-1 (WIF1) gene promoter have been detected in different types of cancer.
|
30649640 |
2019 |
|
Tumor Progression
|
0.030 |
PosttranslationalModification
|
phenotype |
BEFREE |
Epigenetic promoter methylation of Wif1, leading to silencing of its transcription and concomitant up-regulation of Wnt signaling, is a common feature during cancer progression.
|
30574494 |
2018 |
|
Disorder of eye
|
0.010 |
Biomarker
|
group |
BEFREE |
In addition, we highlight the potential of Wif1 research to understand and possibly influence mechanisms underlying eye diseases and regeneration.
|
30574494 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For neoplastic mucosa a five marker panel (SFRP2, SFRP4, WIF1, APC1A, APC2) was accurate in detecting pre-cancerous and invasive neoplasia (AUC = 0.83; 95% CI: 0.79, 0.88), and dysplasia (AUC = 0.88; (0.84, 0.91).
|
30473377 |
2019 |
|
Glioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The expression levels of HOXC6 and WNT inhibitory factor 1 (WIF-1) in the glioma U87 cells after transfection with HOXC6-shRNA were measured by real-time PCR and Western blot． CCK-8, colony formation and EdU assays were used to measure the effects of HOXC6 on U87 cell proliferation, and flow cytometry was used to monitor the changes in the cell cycle and cell apoptosis after transfection with HOXC6-shRNA.
|
30228024 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, it is hoped that increased understanding will be gained concerning DMC's interactive role with microRNA-551a, 5' adenosine monophosphate-activated protein kinase, nuclear factor-κB, Wnt inhibitory factor-1, and heat shock protein 70 to affect the progression of cancer.
|
30076727 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, it is hoped that increased understanding will be gained concerning DMC's interactive role with microRNA-551a, 5' adenosine monophosphate-activated protein kinase, nuclear factor-κB, Wnt inhibitory factor-1, and heat shock protein 70 to affect the progression of cancer.
|
30076727 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrate by both ex vivo and xenograft experiments that inhibiting miR-221/222 expression in a TNBC cell line (MDA-MB-231) suppresses its proliferation, viability, epithelial-to-mesenchymal transition, and migration; whereas expressing miR-221/222 in a non-TNBC line (MCF7) promotes all of the above cancer properties. miR-221/222 achieve so by directly repressing multiple negative regulators of the Wnt/β-catenin signaling pathway, including WIF1, SFRP2, DKK2, and AXIN2, to activate the pathway.
|
30053090 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrate by both ex vivo and xenograft experiments that inhibiting miR-221/222 expression in a TNBC cell line (MDA-MB-231) suppresses its proliferation, viability, epithelial-to-mesenchymal transition, and migration; whereas expressing miR-221/222 in a non-TNBC line (MCF7) promotes all of the above cancer properties. miR-221/222 achieve so by directly repressing multiple negative regulators of the Wnt/β-catenin signaling pathway, including WIF1, SFRP2, DKK2, and AXIN2, to activate the pathway.
|
30053090 |
2018 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
No differences were observed in WIF-1 expression linked to a particular condition, but WIF-1 stain was significantly enhanced in the crypts and lamina propria as inflammation increased in biopsies from patients with both, ulcerative colitis and Crohn's disease.
|
30051904 |
2019 |